valine has been researched along with Hepatitis C in 220 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.45) | 18.2507 |
| 2000's | 3 (1.36) | 29.6817 |
| 2010's | 180 (81.82) | 24.3611 |
| 2020's | 36 (16.36) | 2.80 |
| Authors | Studies |
|---|---|
| Abbass, A; Abdeen, N; Afify, S; Alboraie, M; El Kassas, M; ELshazly, HM; Eltabbakh, M; Emadeldeen, M; Ezzat, S; Farghaly, R; Ghalwash, A; Hamdy, H; Omar, H; Omran, D; Salaheldin, M; Sweedy, A; Tahoon, M | 1 |
| Ali, A; Anwer, S; Hussain Shah, SS; Kashif, M; Nasiri, MI; S Naqvi, SB; Sarwar, H | 1 |
| Cheong, MWL; Khor, SK; Piedagnel, JM | 1 |
| Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH | 1 |
| Öksüz, Z; Serin, MS; Sezgin, O; Temel, GÖ; Üçbilek, E; Yaraş, S | 1 |
| Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S | 1 |
| Abd El-Hameed, M; Dawood, RM; El Ray, AA; Mahmoud Diab, T; Mashaal, AR; Seyam, M; Shemis, MA | 1 |
| Akarca, US; Danış, N; Ersöz, G; Günşar, F; Karasu, Z; Özkahya, M; Toz, H; Turan, İ; Ünal, N; Yılmaz, M | 1 |
| Cecka, F; Cerveny, L; Huliciak, M; Martinec, O; Staud, F; Vokral, I | 1 |
| Anis, AH; Azim, T; Chowdhury, EI; Faruque, MO; Janjua, NZ; Kabir, A; Khan, SI; Rahman, M; Reza, M; Sarker, MS; Shafiq, TKI | 1 |
| Alston-Smith, BL; Cohen, DE; Cramer, YS; Morse, GD; Rosenkranz, SL; Schmidt, J; Sulkowski, M; Venuto, CS; Wyles, DL | 1 |
| Baka-Ćwierz, B; Belica-Wdowik, T; Białkowska, J; Buczyńska, I; Citko, J; Czauż-Andrzejuk, A; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Garlicki, A; Halota, W; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D | 1 |
| Aguilar, H; Asatryan, A; Bondin, M; Cacoub, P; Carvalho, A; Castro, RE; Charafeddine, M; Cohen, DE; Dieterich, D; Felizarta, F; Hu, YB; Khan, N; Marinho, RT; Poordad, F; Siddique, A | 1 |
| Abu Hassan, MR; Gonzalez, YS; Ong, SC; Shafie, AA; Virabhak, S | 1 |
| Afshar, B; Agah, S; Amiriani, T; Fattahi Abdizadeh, M; Fattahi, MR; Hormati, A; Khoshnia, M; Latifnia, M; Majd Jabbari, S; Maleki, I; Malekzadeh, R; Malekzadeh, Z; Mansour-Ghanaei, F; Merat, D; Merat, S; Minakari, M; Moini, M; Mokhtare, M; Poustchi, H; Roozbeh, F; Sharifi, AH; Shayesteh, AA; Shayesteh, E; Sofian, M; Sohrabi, M; Somi, MH | 1 |
| Abdel Moneim, A; Mabrouk, D; Mahmoud, B; Suleiman, HA; Zaky, MY | 1 |
| Ben-Ari, Z; Bruck, R; Cohen-Ezra, O; Deutsch, L; Gozlan, Y; Houri, I; Issachar, A; Katchman, H; Menachem, Y; Mor, O; Shibolet, O; Shlomai, A; Veitsman, E; Zelber-Sagi, S | 1 |
| Balkan, S; Brucker, C; Chhit, D; Dousset, JP; Hang, V; Iwamoto, M; Jolivet, P; Kien, A; Le Paih, M; Ly, S; Marquardt, T; O'Keefe, D; Sann, K; Zhang, M | 1 |
| Barnes, E; Chau, NVV; Cooke, GS; McCabe, L; Pett, SL; Walker, AS; White, IR | 1 |
| Bronowicki, JP; Carrat, F; Chazouillères, O; Chevaliez, S; de Lédinghen, V; Dorival, C; Fontaine, H; Larrey, D; Lusivika-Nzinga, C; Marcellin, P; Metivier, S; Pawlotsky, JM; Pol, S; Samuel, D; Tran, A; Zoulim, F | 1 |
| Agarwal, K; Bestwick, J; Drysdale, K; Elsharkawy, AM; Forton, D; Foster, GR; Gelson, W; Mahomed, F; Mutimer, D; Ntuli, Y; Townley, C | 1 |
| Arai, J; Fukumura, Y; Imai, M; Kato, J; Kojima, K; Kondo, M; Kurokawa, K; Mori, M; Ohki, T; Seki, M; Shibata, C; Tagawa, K; Takagi, K; Toda, N | 1 |
| Barclay, ST; de Bruin, M; Dillon, JF; Donnan, PT; Fraser, A; Hapca, A; Inglis, SK; Radley, A | 1 |
| Doi, Y; Hagiwara, H; Hikita, H; Iio, S; Imai, Y; Kai, Y; Kodama, T; Morishita, N; Sakamori, R; Tahata, Y; Takehara, T; Tamura, S; Tatsumi, T; Urabe, A; Yamada, R; Yamada, T | 1 |
| Devi, S | 1 |
| Chalasani, N; Chayama, K; Dulcey, AE; Frankowski, KJ; Hu, X; Hu, Z; Imamura, M; Irvin, PH; Le, D; Li, K; Liang, TJ; Ma, CD; Marugan, JJ; Osawa, M; Park, SB; Rolt, A; Southall, N; Talley, DC; Teraoka, Y; Uchida, T; Wang, AQ; Xu, X | 1 |
| Burger, DM; Colbers, A; Drenth, JPH; Freriksen, JJM; Greupink, R; Meijerhof, M; Russel, FGM; van Drongelen, J | 1 |
| Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L | 1 |
| Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Rai, P; Rungta, S; Tiwari, P; Verma, A | 1 |
| Bittar, C; Chen, S; Fernandes Campos, GR; Harris, M; Martinelli, ALC; Pereira, LRL; Rahal, P; Souza, FF; Vilela Rodrigues, JP; Ward, J | 1 |
| Mendizabal, M; Piñero, F; Ridruejo, E; Silva, M | 1 |
| Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH | 1 |
| Callegaro, FS; de Camargo Vieira, MC; Gonçalves, WRB; Guerra, RA; Lazaretti-Castro, M; Maeda, SS | 1 |
| Bilal, M; Farooq, N; Hussain, N; Maqsood, M; Rajoka, MSR | 1 |
| Allam, N; Gomaa, A; Waked, I | 1 |
| Balkan, S; Bunreth, V; Craig, J; Dousset, JP; Jolivet, P; Le Paih, M; Marquardt, T; O'Keefe, D; Samley, K; Zhang, M | 1 |
| Draper, B; Hellard, M; Pedrana, A | 1 |
| Hasuike, S; Iwakiri, H; Kuroki, K; Kusumoto, K; Matsuura, Y; Mukuda, T; Nagata, K; Nakamura, K; Ochiai, T; Ozono, Y; Shimoda, K; Tsuchimochi, M | 1 |
| Adeyemi, O; Bhatti, L; Hu, YB; Khatri, A; King, JR; Lalezari, J; Ruane, P; Saag, M; Shulman, NS; Trinh, R; Viani, RM; Wyles, D | 1 |
| Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R | 1 |
| Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Prasad, N; Rai, P; Sharma, RK | 1 |
| Endo, T; Murakami, R; Nakamura, M; Nakamura, N; Narita, I; Shimada, M; Tomita, H; Yamabe, H | 1 |
| Bregigeon, S; Colson, P; Dhiver, C; Lacarelle, B; Menard, A; Poizot-Martin, I; Ravaux, I; Ressiot, E; Ruiz, JM; Solas, C; Taton, A; Tomei, C | 1 |
| Chevaliez, S; Fourati, S; François, M; Hézode, C; Mallat, A; Pawlotsky, JM; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A | 1 |
| Deming, P; Martin, MT | 1 |
| Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M | 1 |
| Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A | 1 |
| Goto, H; Hattori, M; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Katano, Y; Kawashima, H; Kuzuya, T; Tachi, Y | 1 |
| Bao, Y; Calleja, JL; Craxí, A; Dieterich, D; Flisiak, R; Martinez, M; Pangerl, A; Roberts, SK; Wedemeyer, H; Zhang, Z; Zuckerman, E | 1 |
| Alves, K; Burroughs, M; Chayama, K; Kato, K; Kumada, H; Pilot-Matias, T; Redman, R; Rodrigues, L; Sato, K; Setze, C; Suzuki, F; Toyoda, H; Zhang, X | 1 |
| Bañares, R; Casafont, F; Castellote, J; Castells, L; Cuervas-Mons, V; Espinosa, MD; Fernández, I; García-Gonzalez, M; González, A; González-Diéguez, L; Herrero, JI; Llaneras, J; Londoño, MC; Lorente, S; Molina Pérez, E; Montero Alvarez, JL; Narváez, I; Otero, A; Pascasio, JM; Pascual, S; Pons, JA; Prieto, M; Salcedo, M; Sánchez-Antolín, G; Sousa, JM; Testillano, M; Vinaixa, C | 1 |
| Bielen, R; Bourgeois, S; Brixko, C; Cool, M; Cools, W; D'heygere, F; De Galocsy, C; Decaestecker, J; Janssens, F; Moreno, C; Mulkay, JP; Nevens, F; Robaeys, G; Van Overbeke, L; Van Steenkiste, C; Van Vlierberghe, H; Vanwolleghem, T; Verlinden, W | 1 |
| Amemiya, M; Hayashi, N; Koshima, Y; Kuriyama, S; Matsuyama, M; Morisawa, N; Satoh, JI; Yokoo, T | 1 |
| Bellissant, E; Ben Ali, Z; Boglione-Kerrien, C; Guyader, D; Jezequel, C; Lemaitre, F; Tron, C; Verdier, MC | 1 |
| Bhayani, V; Desai, P; Kabrawala, M; Mehta, R; Nandwani, S; Parekh, V; Patel, S | 1 |
| Britto, K; Cameron, R; Cheung, W; Kemp, W; Roberts, SK | 1 |
| Abunimeh, M; Agarwal, K; Charafeddine, M; Cohen, DE; Cohen, E; Foster, GR; Fu, B; Gane, E; Pilot-Matias, T; Pothacamury, RK; Shafran, SD; Shaw, D | 1 |
| Akamatsu, N; Eguchi, S; Furukawa, H; Goto, R; Honda, M; Ikegami, T; Inomata, Y; Ishiyama, K; Kitagawa, Y; Kokudo, N; Ku, Y; Kuramitsu, K; Maehara, Y; Ohdan, H; Okajima, H; Shimada, M; Shinoda, M; Soyama, A; Taketomi, A; Ueda, Y; Uemoto, S; Yanaga, K; Yoshizumi, T | 1 |
| Rostkowska, K; Simon, K; Szymanek-Pasternak, A | 1 |
| Arama, V; Brisc, C; Caruntu, F; Cijevschi, C; Curescu, M; Gheorghe, C; Gheorghe, L; Iacob, R; Iacob, S; Simionov, I; Sirli, R; Sporea, I; Stanciu, C; Trifan, A | 1 |
| Alves, MP; Banda, D; Behrendt, P; Colpitts, CC; Manns, MP; Menzel, N; Meuleman, P; Perin, P; Pfaender, S; Pietschmann, T; Schang, LM; Steinmann, E; Thiel, V; Vondran, FWR | 1 |
| Chodick, G; Koren, G; Mehta, D; Pinsky, B; Samp, JC; Shalev, V; Weil, C | 1 |
| Ariaudo, A; Avataneo, V; Boglione, L; Carcieri, C; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Favata, F; Guido, F; Mornese Pinna, S | 1 |
| Frey, A; Gerken, G; Herzer, K; Piras-Straub, K; Timm, J; Walker, A | 1 |
| Eurich, D; Globke, B; Pratschke, J; Schott, E; Teegen, EM | 1 |
| Angelico, M; Biolato, M; Calvaruso, V; Carrai, P; Craxì, A; D'offizi, G; Fagiuoli, S; Guaraldi, G; Lenci, I; Lionetti, R; Loiacono, L; Mancusi, RL; Mazzarelli, C; Milana, M; Montalbano, M; Piccolo, P; Valente, G; Visco-Comandini, U | 1 |
| Buti, M; Chen, Q; Esteban, JI; Esteban, R; Garcia-Cehic, D; Gregori, J; Llorens, M; Nieto-Aponte, L; Ordeig, L; Perales, C; Quer, J; Riveiro-Barciela, M; Rodriguez-Frias, F; Soria, ME | 1 |
| Chen, TY; Dong, J; Gao, H; He, YL; Hu, CH; Liu, JF; Ren, DF; Yan, TT; Yang, SJ; Yang, Y; Zhao, YR; Zhu, L | 1 |
| Agrati, C; Ammassari, A; Antinori, A; Fabbri, G; Libertone, R; Notari, S; Tempestilli, M | 1 |
| Hirayama, T; Honda, A; Ikegami, T; Kohjima, M; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Yara, SI | 1 |
| Elhenawee, M; Hashem, H; Ibrahim, AE; Saleh, H | 1 |
| El-Amin, H; El-Khayat, H; Fouad, Y; Kamal, EM; Maher, M; Mohamed, HI; Risk, A | 1 |
| Bao, Y; Grunow, N; Hudgens, S; Mehta, D; Pinsky, B; Saab, S | 1 |
| Muñoz-Medina, L; Navarro-Navarro, I; Navarro-Triviño, FJ; Ruiz-Villaverde, R | 1 |
| Bernstein, DE; Feld, JJ; Ferenci, P; Larsen, L; Tatsch, F; Vlierberghe, HV; Younes, Z | 1 |
| Ansari, MA; Barnes, E; Bonsall, D; Bowden, R; Brown, A; Ip, CLC; Magri, A; Nguyen, D; Piazza, P; Simmonds, P; Smith, D; Trebes, A | 1 |
| Fan, R; Hou, J; Liang, X; Sun, J | 1 |
| Collado, A; de Los Santos, I; Macías, J; Mancebo, M; Merino, D; Morano-Amado, LE; Palacios, R; Pérez, AB; Pérez-Pérez, M; Pineda, JA; Ríos, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F | 1 |
| Cao, Y; Chen, D; Gai, K; Liu, B; Liu, X; Lu, D; Lu, Q; Qin, H; Shen, H; Song, W; Wang, X; Xu, H; Zhang, Y | 1 |
| Hu, J; Li, C | 1 |
| Applegate, TL; Bhagani, S; Cooke, G; Dore, GJ; Gane, E; Grebely, J; Marks, P; Martinello, M; Matthews, GV; Nelson, M; Orkin, C; Pagani, N; Petoumenos, K; Tu, E | 1 |
| Bandeira de Mello Brandao, A; Costabeber, AM; Cracco Cantisani, GP; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Medeiros Fleck, A; Meine, MH; Mucenic, M; Sacco, FKF; Soares Schlindwein, E; Zanotelli, ML | 1 |
| Alao, H; Cam, M; Fourie, NH; Ghany, MG; Henderson, WA; Keembiyehetty, C; Li, Q; Liang, TJ; Park, H; Rehermann, B; Serti, E; Suarez, D; Wright, EC; Zhang, F | 1 |
| Abbas, B; Asem, N; Elsharkawy, A; Esmat, G; Gomaa, A; Hassany, M; Maged, A; Mehrez, M; Mostafa, Z; Soliman, M | 1 |
| Cázares-Cortázar, A; Gaytán-Martínez, J; Gómez-Torres, ME; Martínez-Rodríguez, ML; Mata-Marín, JA; Ocaña-Mondragón, A; Ribas-Aparicio, RM; Uribe-Noguez, LA | 1 |
| Esposito, I; Marciano, S; Trinks, J | 1 |
| Abo-Zeid, MN; Atia, NN; El-Gizawy, SM; El-Shaboury, SR | 1 |
| Abe-Chayama, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Ishida, Y; Kan, H; Makokha, GN; Miki, D; Ochi, H; Osawa, M; Saito, Y; Tateno, C; Teraoka, Y; Tsuge, M; Uchida, T | 1 |
| Chen, L; Li, B; Ma, L; Qing, J; Zhai, PB; Zhang, LQ | 1 |
| Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S | 1 |
| Fujioka, SI; Hagihara, H; Hashimoto, N; Ikeda, F; Iwasaki, Y; Kariyama, K; Kawaguchi, M; Kobashi, H; Kubota, J; Miyatake, H; Mori, C; Morimoto, Y; Moriya, A; Okada, H; Sakaguchi, K; Takaguchi, K; Takaki, A; Takayama, H; Takeuchi, Y; Wada, N; Yasunaka, T | 1 |
| Jagadabi, V; Mahesh, K; Nagaraju, D; Nagendra Kumar, PV; Pamidi, S; Ramaprasad, LA | 1 |
| Fukuhara, T; Furusho, N; Harada, N; Ikegami, T; Itoh, S; Kato, M; Maehara, Y; Shimoda, S; Soejima, Y; Yoshizumi, T | 1 |
| Bartlett, C; Curd, A; Harris, M; Peckham, M | 1 |
| Arias, M; Belmar, L; González, LN; Laguno, M; Llovet, LP; Londoño, MC; Maduell, F; Mallolas, J; Martínez-Rebollar, M; Ojeda, R; Rodas, L; Rossi, F; Ugalde, J | 1 |
| Lee, TY; Yang, SS | 1 |
| Biggs, BA; Kanhutu, K; Sasadeusz, J; Schulz, TR; Watkinson, S | 1 |
| Giorgi, C; Hoffmann, HH; Kuchay, S; Li, J; Pagano, M; Pinton, P; Rice, CM; Saeed, M | 1 |
| Jung, BH; Lee, SG; Park, JI | 1 |
| Enomoto, M; Hai, H; Kawada, N; Kumada, H; Okada, M; Tamori, A; Uchida-Kobayashi, S | 1 |
| Hsiang, JC; Kumar, R; Tan, J; Thurairajah, PH | 1 |
| Bakr, MA; El Maghrabi, HM; Elmowafy, AY; Elwasif, SM; Zahab, MA | 1 |
| Garimella, T; Ishikawa, H; Li, H; Osawa, M; Shiozaki, T; Ueno, T | 1 |
| Garimella, T; Green, M; Osawa, M; Shiozaki, T; Ueno, T | 1 |
| Asahina, Y; Doi, A; Hikita, H; Kai, Y; Kato, T; Kodama, T; Murayama, A; Nakabori, T; Nitta, S; Saito, Y; Sakamori, R; Suemizu, H; Tahata, Y; Takehara, T; Tatsumi, T; Yamada, R | 1 |
| Clément, V; Raimond, V | 1 |
| Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I | 1 |
| Bladowska, J; Ejma, M; Fleischer-Stępniewska, K; Inglot, M; Knysz, B; Marciniewicz, E; Małyszczak, K; Pawłowski, T; Podgórski, P; Rymer, W; Sąsiadek, M; Waliszewska-Prosół, M; Żelwetro, A | 1 |
| Aziz, T; Hanif, FM; Lail, G; Luck, NH; Mandhwani, R | 1 |
| Hou, MC; Huang, YH; Lan, KH; Lan, KL; Lee, WP; Liao, SX | 1 |
| Chen, CY; Chen, DS; Chen, PJ; Cheng, PN; Chiu, YC; Fang, YJ; Hsieh, TY; Kao, JH; Lin, CL; Liu, CH; Liu, CJ; Peng, CY; Shih, YL; Su, TH; Yang, HC; Yang, SS | 1 |
| Brandão-Mello, CE; Costa, VD; de Souza Rodrigues, LLLX; do Amaral Mello, FC; Dos Santos Silva, PGC; Lampe, E; Nunes, EP | 1 |
| Chu, CJ; Hou, MC; Huang, YH; Wu, SH | 1 |
| Alados-Arboledas, JC; Aldámiz-Echevarría, T; Casado, M; Chueca, N; García, F; García-Bujalance, S; García-Deltoro, M; Lara-Pérez, MM; Martínez-Sapiña, AM; Merino, D; Pascasio, JM; Pérez, AB; Pineda, JA; Poyato, A; Rivero-Juárez, A; Rosales-Zábal, JM; Salmerón, J; Téllez, F; Vera-Méndez, FJ; Vivancos-Gallego, MJ | 1 |
| Alavi, M; Dore, GJ; Grebely, J; Hajarizadeh, B; Kaveh-Ei, S; Malekzadeh, R; Merat, S; Poustchi, H; Rahimi-Movaghar, A; Shadloo, B | 1 |
| Wahid, B | 1 |
| Chen, J; Li, J; Lu, H; Wang, J; Xiao, H; Yang, F | 1 |
| Barrail-Tran, A; Botta-Fridlund, D; Cagnot, C; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; De Ledinghen, V; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fougerou-Leurent, C; Gelé, T; Goldwirt, L; Houssel-Debry, P; Kamar, N; Laforest, C; Lavenu, A; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Samuel, D; Taburet, AM | 1 |
| Ataíde, EC; Boin, IFSF; Santos, AG; Stucchi, RSB; Zanaga, LP | 1 |
| Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M | 1 |
| Corouge, M; Pol, S; Vallet-Pichard, A | 1 |
| Dieterich, DT; Martel-Laferrière, V | 1 |
| Asselah, T; Halfon, P; Marcellin, P; Schinazi, R | 1 |
| Ford, N; Fortunak, J; Hill, A; Khoo, S; Simmons, B | 1 |
| Kanda, T; Nakamoto, S; Shirasawa, H; Wu, S; Yokosuka, O | 1 |
| Al-Mawsawi, LQ; Chen, SH; Chen, Z; Chu, V; Du, Y; Ke, R; Lin, CY; Lloyd-Smith, JO; Loverdo, C; Olson, CA; Qi, H; Remenyi, R; Su, SY; Sun, R; Truong, S; Wu, NC; Wu, TT; Zhong, W | 1 |
| Andreone, P; Bernstein, B; Colombo, MG; Enejosa, JV; Ferenci, P; Horsmans, Y; Hu, YB; Koksal, I; Maieron, A; Müllhaupt, B; Podsadecki, T; Reesink, HW; Rodrigues, L; Weiland, O | 1 |
| Barth, H; Baumert, TF; Bukh, J; Doffoël, M; Fofana, I; Habersetzer, F; Heydmann, L; Patel, AH; Soulier, E; Xiao, F; Zeisel, MB | 1 |
| Adler, H; Lambert, JS | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E | 1 |
| Izumi, N | 1 |
| Borgia, G; Buonomo, AR; Gentile, I | 1 |
| Stirnimann, G | 1 |
| Firpi, RJ; Hilgenfeldt, E | 1 |
| Beyer, J; Campbell, A; Collins, C; DeGoey, D; Kati, W; Koev, G; Krishnan, P; Mistry, N; Molla, A; Pilot-Matias, T; Reisch, T; Setze, C; Williams, L; Xie, W | 1 |
| Serfaty, L | 1 |
| Berger, KL; Chukkapalli, V; Deiters, A; Kelly, SM; Randall, G; Thomas, M | 1 |
| Bennett, M; Bernstein, D; Cooper, JN; Freilich, BF; Ghalib, R; Gitlin, N; Harlan, W; Hawkins, T; Hennicken, D; Hughes, EA; Kowdley, KV; Lalezari, JP; Lawitz, E; McPhee, F; Nelson, DR; Oguchi, G; Ortiz-Lasanta, G; Pockros, PJ; Rabinovitz, M; Rana, K; Ravendhran, N; Sheikh, AM; Thuluvath, PJ; Varunok, P; Younes, ZH | 1 |
| Gutierrez, J; Martin, P; Trivella, JP | 1 |
| Awni, W; Badri, P; Bernstein, B; Coakley, E; Cohen, D; Ding, B; Dutta, S; Menon, R; Podsadecki, T | 1 |
| Bartlett, C; Griffin, S; Harris, M; Ross-Thriepland, D; Shaw, J; Stewart, H | 1 |
| Hayward, P | 1 |
| Manns, MP; Wedemeyer, H; Zeuzem, S | 1 |
| Bondeson, K; Kjellin, M; Lannergard, A; Lennerstrand, J; Lindström, I; Palanisamy, N; Wesslén, L | 1 |
| Botta, D; Coilly, A; D'Alteroche, L; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Durand, F; Fougerou-Leurent, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Pageaux, GP; Petrov-Sanchez, V; Radenne, S; Sebagh, M; Silvain, C | 1 |
| Andreone, P; Gamal, N | 1 |
| Dusheiko, G; Kalafateli, M; Manousou, P | 1 |
| Hernandez, D; McPhee, F; Sims, K; Ueland, J; Yang, X; Yin, PD; Yu, F; Zhou, N | 1 |
| Forns, X; Gambato, M; Lens, S; Mariño, Z | 1 |
| Chayama, K; Fujiyama, S; Hu, W; Hughes, E; Ishikawa, H; Ito, T; Itoh, Y; Karino, Y; Kawakami, Y; Kumada, H; Linaberry, M; McPhee, F; Suzuki, F; Suzuki, Y; Tamura, E; Toyota, J; Ueki, T | 1 |
| Badri, PS; Dutta, S; King, JR; McGovern, BH; Menon, RM; Polepally, AR | 1 |
| Kalsekar, A; Kelley, C; Kim, S; Mu, F; Noviello, S; Signorovitch, J; Song, J; Swallow, E; Yuan, Y | 1 |
| Rao, HY; Wang, Y; Wei, L; Xie, XW | 1 |
| Antinori, S; Calvi, E; Milazzo, L; Regalia, E; Sollima, S; Torre, A | 1 |
| Mohammad, RA; Regal, RE; Smith, MA | 1 |
| Belema, M; Cockett, M; Fridell, RA; Gao, M; Hewawasam, P; Johnson, BM; Kadow, J; Kramer, M; Langley, DR; Lemm, JA; Liu, M; Meanwell, NA; Moulin, F; Nophsker, MJ; Nower, P; O'Boyle, DR; Rigat, K; Roberts, SB; Sun, JH; Tu, Y; Wang, C; Wang, YK | 1 |
| Abe, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Ishida, Y; Kan, H; Miki, D; Miyaki, E; Ochi, H; Tateno, C; Tsuge, M; Uchida, T | 1 |
| Gordon, SC; Jafri, SM | 1 |
| Gonzalez, YS; Huber, C; Juday, T; Saab, S; Wang, A | 1 |
| Beyer, J; Burroughs, M; Chayama, K; Collins, C; Krishnan, P; Kumada, H; Pilot-Matias, T; Redman, R; Reisch, T; Rodrigues, L; Schnell, G; Setze, C; Tripathi, R; Zhang, X | 1 |
| Awni, W; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Wang, H | 1 |
| Cattaneo, D; Clementi, E; Gervasoni, C; Milazzo, L; Riva, A | 1 |
| Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N | 1 |
| Abunimeh, M; Bennett, M; Bernstein, DE; Cohen, DE; Cohen, E; Khatri, A; Lawitz, E; Mantry, PS; Pockros, PJ; Podsadecki, T; Reddy, KR; Shulman, NS; Sulkowski, MS; Wang, D | 1 |
| Ackerman, P; Bhore, R; Luetkemeyer, AF; McDonald, C; Noviello, S; Ramgopal, M | 1 |
| Cattaneo, D; D'Avolio, A; Gervasoni, C; Micheli, V; Milazzo, L; Sollima, S | 1 |
| Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI | 1 |
| Ampuero, J; Reddy, KR; Romero-Gomez, M | 1 |
| Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A | 1 |
| Tanaka, Y | 1 |
| Casanovas, T; Niubó, J; Roca, J | 1 |
| Bryce, CL; Chidi, AP; Donohue, JM; Fine, MJ; Landsittel, DP; Myaskovsky, L; Rogal, SS; Smith, KJ; Switzer, GE; Tsung, A | 1 |
| Abergel, A; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; d'Alteroche, L; de Ledinghen, V; di Martino, V; Diallo, A; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Rohel, A; Rossignol, E; Samuel, D; Tran, A | 1 |
| Andreis, S; Basso, M; Cattelan, AM; Cavinato, S; Dal Bello, F; Loregian, A; Messa, L; Nannetti, G; Palù, G; Parisi, SG; Scaggiante, R | 1 |
| Antoniazzi, S; Bolis, M; Carnovale, C; Clementi, E; Gentili, M; Landonio, S; Magni, C; Niero, F; Radice, S | 1 |
| Marshall, G | 1 |
| Awni, WM; Dutta, S; Eckert, D; Khatri, A; Menon, RM; Mensing, S; Podsadecki, TJ; Polepally, AR; Sharma, S | 1 |
| Mendes, LC; Miotto, N; Stucchi, RS; Vigani, AG; Zanaga, LP | 1 |
| Kasai, H; Moriishi, K; Otoguro, T; Tanaka, T; Yamashita, A | 1 |
| Ashimkhanova, A; Kaliaskarova, K; Yesmembetov, K | 1 |
| Botta-Fridlund, D; Hachicha, M | 1 |
| Alonso, A; Franco, A; Gentil, MA; González-Corvillo, C; Hernández-Marrero, D; Jiménez-Martín, C; Lauzurica, LR; Perelló, M; Sánchez-Fructuoso, A; Zarraga, S | 1 |
| Ahmed, M; Barakat, K; Houghton, M; Pal, A | 1 |
| Hernandez, D; McPhee, F; Zhou, N | 1 |
| Fujisaka, Y; Inoue, J; Kakazu, E; Kanno, A; Kobayashi, T; Kogure, T; Miura, M; Morosawa, T; Nakamura, T; Ninomiya, M; Shimosegawa, T; Takai, S; Umetsu, T; Wakui, Y | 1 |
| Huang, J; Liao, H; Tan, P; Yan, X; Zhu, Z | 1 |
| Yu, ML | 1 |
| Hagiwara, H; Hikita, H; Hiramatsu, N; Iio, S; Imai, Y; Kai, Y; Kato, T; Kondo, Y; Morishita, N; Murai, K; Naito, M; Nakabori, T; Nishiuchi, M; Oze, T; Sakamori, R; Suemizu, H; Takehara, T; Tamura, S; Tatsumi, T; Tsutsui, S; Yakushijin, T; Yamada, R | 1 |
| Abad, S; Albalate, M; de Sequera, P; Hernández, E; López-Gómez, JM; Macías, N; Mérida, E; Milla, M; Vega, A | 1 |
| Baker, MM; Belal, TS; El-Kafrawy, DS; Mahrous, MS | 1 |
| Backus, LI; Belperio, PS; Bhattacharya, D; Goetz, MB; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Lim, SG | 1 |
| King, JR; Menon, RM | 1 |
| Bhasin, D; Pollinger, H; Rubin, RA; Shrestha, R; Stein, L; Tracy, B | 1 |
| Alric, L; Bellier, B; Cacoub, P; Comarmond, C; Costopoulos, M; Desbois, AC; Fontaine, H; Garrido, M; Klatzmann, D; Le Garff-Tavernier, M; Maciejewski, A; Musset, L; Pol, S; Poynard, T; Rosenzwajg, M; Saadoun, D; Si Ahmed, SN | 1 |
| Conway, B; Lazzarin, A; Luetkemeyer, A; Molina, JM; Nelson, M; Portsmouth, S; Romanova, S; Rubio, R; Srinivasan, S; Xu, D | 1 |
| Casari, S; Castelli, F; Festa, E; Izzo, I; Lanza, P; Odolini, S; Vavassori, A; Zaltron, S | 1 |
| Alric, L; Bouyer, AS; Cacoub, P; Comarmond, C; de Saint Martin, L; Ferfar, Y; Hezode, C; Musset, L; Pol, S; Poynard, T; Resche Rigon, M; Saadoun, D; Si Ahmed, SN | 1 |
| Chae, HB; Cho, BW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Lee, BS; Lee, SH; Lee, TH; Song, IH | 1 |
| Belema, M; Chien, C; Colonno, RJ; Fridell, RA; Gao, M; Grasela, DM; Hamann, LG; Knipe, JO; Langley, DR; Lemm, JA; Meanwell, NA; Nettles, RE; Nguyen, VN; O'Boyle, DR; Serrano-Wu, MH; Snyder, LB; Sun, JH; Wang, C | 1 |
| Schmitz, J | 1 |
| Bifano, M; Fridell, RA; Gao, M; Huang, X; Kienzle, B; Nettles, RE; Nower, P; O'Boyle, DR; Qiu, D; Roberts, S; Sun, JH; Valera, L; Wang, C | 1 |
| Gish, RG; Meanwell, NA | 1 |
| Razonable, RR | 1 |
| Lee, C | 1 |
| Chayama, K; Hughes, E; Ikeda, K; Ishikawa, H; Karino, Y; Kumada, H; McPhee, F; Takahashi, S; Toyota, J; Watanabe, H | 1 |
| Dieterich, D | 1 |
| Arnold, ME; Bifano, M; Cojocaru, L; Jiang, H; Kandoussi, H; Liu, Y; Ryan, J; Wang, X; Zeng, J | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mineta, R; Miyakawa, Y; Saito, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S | 1 |
| Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA | 1 |
| Chatterjee, A; Perelson, AS; Smith, PF | 1 |
| Suk-Fong Lok, A | 1 |
| Brown, TJ; McCrary, M; Tyring, SK | 1 |
| Afifi, R; Benazzouz, M; Benjelloun, S; Chafik, A; El Feydi, AE; El Kihal, L; Ezzikouri, S; Hassar, M; Pineau, P | 1 |
| Daielli, C; Maccabruni, A; Martinetti, M; Pacati, I; Salvaneschi, L | 1 |
39 review(s) available for valine and Hepatitis C
| Article | Year |
|---|---|
Hepatitis C-Associated Osteosclerosis: Improvement After Treatment with Sofosbuvir, Daclatasvir, and Ibandronate: Case Report and Literature Review.
Topics: Carbamates; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Osteosclerosis; Pyrrolidines; Sofosbuvir; Valine | 2021 |
Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report.
Topics: Aged; Antiviral Agents; Carbamates; Cryoglobulinemia; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine | 2017 |
Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.
Topics: Anilides; Antiviral Agents; Carbamates; Comorbidity; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2017 |
Cutaneous eruptions by new therapies against hepatitis C virus infection. Not as common as we presumed.
Topics: 2-Naphthylamine; Adrenal Cortex Hormones; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Eruptions; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Histamine Antagonists; Humans; Incidence; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C.
Topics: Administration, Oral; Antiviral Agents; Benzazepines; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Japan; Pyrrolidines; Sulfonamides; Valine | 2018 |
Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs.
Topics: Antiviral Agents; Carbamates; Cost-Benefit Analysis; Economics, Medical; France; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Therapies, Investigational; Valine | 2019 |
Treatment of hepatitis C virus genotype 3-infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Standard of Care; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Viral Proteins | 2014 |
Treating HCV in HIV 2013: on the cusp of change.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Sofosbuvir; Thiazoles; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
HCV direct-acting antiviral agents: the best interferon-free combinations.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Hepatitis C virus NS5A inhibitors and drug resistance mutations.
Topics: Animals; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Mutation; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2014 |
Daclatasvir for the treatment of hepatitis C virus infection.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Efficacy of daclatasvir in hepatitis C virus.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Valine; Viral Nonstructural Proteins | 2014 |
Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Proline; RNA, Viral; Valine; Viral Nonstructural Proteins | 2014 |
Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Proline; Ribavirin; Valine; Viral Nonstructural Proteins | 2014 |
Hepatitis C management in post-transplant patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load | 2015 |
How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
A 4-drug combination (Viekira Pak) for hepatitis C.
Topics: 2-Naphthylamine; Anilides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Molecular Structure; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2015 |
Advances in hepatitis C therapies.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver Transplantation; Pyrrolidines; Simeprevir; Sofosbuvir; Valine | 2015 |
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Valine | 2016 |
Daclatasvir (Daklinza) for HCV genotype 3 infection.
Topics: Animals; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine | 2015 |
Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Nausea; Pyrrolidines; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2016 |
The safety of daclatasvir for the treatment of hepatitis C.
Topics: Administration, Oral; Animals; Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Valine; Virus Replication | 2015 |
Technivie for HCV genotype 4 infection.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Valine | 2015 |
Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Odds Ratio; Prospective Studies; Pyrrolidines; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Valine | 2016 |
[Latest Treatment of Viral Hepatitis--Overcoming Hepatitis C and Reactivation of Hepatitis B].
Topics: Anilides; Antineoplastic Agents; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; DNA, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Immunoassay; Immunosuppressive Agents; Interferons; Interleukins; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ritonavir; Rituximab; Sensitivity and Specificity; Sulfonamides; Transfusion Reaction; Valine; Virus Activation | 2016 |
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load | 2017 |
HCV management in resource-constrained countries.
Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine | 2017 |
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
Topics: 2-Naphthylamine; Anilides; Anti-Retroviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Ritonavir; Substance-Related Disorders; Sulfonamides; Uracil; Valine | 2017 |
The NS5A replication complex inhibitors: difference makers?
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Discovery; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir | 2011 |
Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Discovery; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Treatment Outcome; Valine; Viral Nonstructural Proteins; Virus Replication | 2011 |
Hepatitis C viral kinetics: the past, present, and future.
Topics: Antiviral Agents; Carbamates; Deoxycytidine; Hepacivirus; Hepatitis C; Humans; Imidazoles; Models, Biological; Oligopeptides; Protease Inhibitors; Pyrrolidines; Silybin; Silymarin; Valine | 2013 |
HCV NS5A inhibitors in development.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine; Viral Nonstructural Proteins; Virus Replication | 2013 |
Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Cytomegalovirus Infections; Famciclovir; Foscarnet; Guanine; Hepatitis B; Hepatitis C; Herpes Genitalis; Herpes Simplex; Herpesvirus 3, Human; Herpesvirus 8, Human; Humans; Papillomavirus Infections; Sarcoma, Kaposi; Skin Diseases, Viral; Valacyclovir; Valine | 2002 |
32 trial(s) available for valine and Hepatitis C
| Article | Year |
|---|---|
Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s.
Topics: 2-Naphthylamine; Acquired Immunodeficiency Syndrome; Adult; Anilides; Antiviral Agents; Coinfection; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Raltegravir Potassium; Ritonavir; Sulfonamides; Uracil; Valine | 2020 |
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Neoplasms; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2020 |
Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Female; Genotype; Glycated Hemoglobin; Hepacivirus; Hepatitis C; Humans; Imidazoles; Inflammation; Insulin Resistance; Interleukin-1beta; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2020 |
The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.
Topics: Administration, Oral; Antiviral Agents; Bayes Theorem; Carbamates; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Vietnam | 2020 |
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Opiate Substitution Treatment; Outcome Assessment, Health Care; Pharmacists; Pyrrolidines; Scotland; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine | 2020 |
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Anti-Retroviral Agents; Body Mass Index; Carbamates; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine | 2017 |
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Internationality; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quality of Life; Regression Analysis; Ribavirin; Ritonavir; Severity of Illness Index; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Internationality; Lactams, Macrocyclic; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Australia; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; England; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Intention to Treat Analysis; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; New Zealand; Proline; Prospective Studies; Ribavirin; Ritonavir; RNA, Viral; Safety; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients.
Topics: Adult; Aged; Amino Acid Substitution; Benzazepines; Carbamates; Drug Combinations; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Logistic Models; Male; Middle Aged; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2019 |
Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
Topics: Aged; Brazil; Carbamates; Drug Resistance, Viral; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Mutation; Pyrrolidines; RNA, Viral; Sequence Analysis, RNA; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2019 |
An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Ill-Housed Persons; Imidazoles; Iran; Male; Middle Aged; Prevalence; Pyrrolidines; Sofosbuvir; Substance Abuse, Intravenous; Valine | 2019 |
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrrolidines; Ritonavir; Tenofovir; Valine; Viral Nonstructural Proteins; Young Adult | 2013 |
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Puerto Rico; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; United States; Uracil; Valine; Viral Load | 2014 |
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Time Factors; Uridine Monophosphate; Valine; Young Adult | 2015 |
Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.
Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Area Under Curve; Carbamates; Cyclopropanes; Cyclosporine; Drug Administration Schedule; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Sulfonamides; Tacrolimus; Uracil; Valine; Young Adult | 2015 |
Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Topics: Antiviral Agents; Belgium; Carbamates; Cholestasis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2015 |
Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
Topics: Adult; Aged; Antiviral Agents; Asian People; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2016 |
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genetics, Population; Hepacivirus; Hepatitis C; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Polymorphism, Genetic; Proline; Ritonavir; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins | 2016 |
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2016 |
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2016 |
Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Dosage Calculations; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Ritonavir; Sulfonamides; Tacrolimus; Uracil; Valine; Young Adult | 2016 |
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Topics: Aged; Antiviral Agents; Belgium; Carbamates; Compassionate Use Trials; Female; France; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Protease Inhibitors; Pyrrolidines; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.
Topics: Adult; Aged; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Interferons; Male; Middle Aged; Pyrrolidines; Ribavirin; Treatment Outcome; Valine; Viral Load | 2017 |
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Topics: Adolescent; Adult; Animals; Antiviral Agents; Carbamates; Cell Line; Chlorocebus aethiops; Drug Resistance, Viral; Female; Genotype; HeLa Cells; Hepacivirus; Hepatitis C; Humans; Imidazoles; Inhibitory Concentration 50; Male; Middle Aged; Pyrrolidines; Time Factors; Valine; Vero Cells; Viral Load; Viral Nonstructural Proteins; Young Adult | 2010 |
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.
Topics: Carbamates; Double-Blind Method; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Phenotype; Pyrrolidines; Replicon; RNA, Viral; Valine; Viral Nonstructural Proteins; Virus Replication | 2011 |
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Diarrhea; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Humans; Imidazoles; Incidence; Interferon-alpha; Isoquinolines; Japan; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Failure; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2012 |
149 other study(ies) available for valine and Hepatitis C
| Article | Year |
|---|---|
Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2021 |
RP-HPLC method development and validation for quantification of daclatasvir dihydrochloride and its application to pharmaceutical dosage form.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Hepatitis C; Imidazoles; Limit of Detection; Pyrrolidines; Reproducibility of Results; Tablets; Valine | 2021 |
Ravidasvir: equitable access through an alternative drug development pathway.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Development; Female; Hepatitis C; Humans; Male; Middle Aged; Valine | 2021 |
Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Organ Transplantation; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2022 |
hsa-miR-17-5p: A Possible Predictor of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin Therapy Efficacy in Hepatitis C Infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; MicroRNAs; Proline; Ribavirin; Ritonavir; RNA, Messenger; Sulfonamides; Toll-Like Receptor 2; Treatment Outcome; Uracil; Valine | 2022 |
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2022 |
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Fibrosis; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Leukocytes, Mononuclear; Pyrrolidines; Ribavirin; RNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2022 |
Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Female; Hepacivirus; Hepatitis C; Humans; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Postoperative Complications; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Tacrolimus; Uracil; Valine | 2019 |
Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.
Topics: Aged; Animals; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Caco-2 Cells; Carbamates; Drug Interactions; Female; Fluorenes; Hepatitis C; HIV Infections; Humans; Imidazoles; Intestines; Lopinavir; Male; Maraviroc; Middle Aged; Pyrrolidines; Rats; Rats, Wistar; Ritonavir; Saquinavir; Valine; Zidovudine | 2019 |
Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Topics: Adult; Aged; Antiviral Agents; Bangladesh; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Prospective Studies; Pyrrolidines; RNA, Viral; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2019 |
Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Prognosis; Proline; Retrospective Studies; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2020 |
Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Genotype; Hepatitis C; Humans; Lactams, Macrocyclic; Malaysia; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2020 |
The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Pyrrolidines; Renal Dialysis; Renal Insufficiency; Safety; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
Topics: Antiviral Agents; Cambodia; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Prospective Studies; Pyrrolidines; Sofosbuvir; Valine | 2020 |
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; England; Female; Fluorenes; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine; Young Adult | 2020 |
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Fatal Outcome; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pyrrolidines; Radiofrequency Ablation; Recurrence; Sulfonamides; Valine; Viral Load | 2020 |
Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
Topics: Aged; Antiviral Agents; Carbamates; Case-Control Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Mutation; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Failure; Valine; Viral Nonstructural Proteins | 2020 |
Ukrainian health authorities adopt hepatitis C project.
Topics: Antiviral Agents; Carbamates; Delivery of Health Care; Drug Therapy, Combination; Drugs, Generic; Health Plan Implementation; Hepacivirus; Hepatitis C; Humans; Imidazoles; Physicians; Pyrrolidines; Sofosbuvir; Ukraine; Valine | 2020 |
Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion.
Topics: Animals; Antiviral Agents; Carbamates; Disease Models, Animal; Dogs; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Mice; Pyrrolidines; Rats; Rats, Sprague-Dawley; Valine; Viral Envelope Proteins; Virus Internalization | 2020 |
Transfer of daclatasvir and sofosbuvir's main metabolite, GS-331007, across the human placenta ex vivo.
Topics: Antiviral Agents; Carbamates; Female; Hepatitis C; Humans; Imidazoles; Maternal-Fetal Exchange; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidines; Sofosbuvir; Uridine; Valine | 2020 |
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2021 |
Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Renal Insufficiency; Sofosbuvir; Treatment Outcome; Valine; Young Adult | 2021 |
A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
Topics: Antiviral Agents; Brazil; Carbamates; Cell Line, Tumor; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Mutation; Pyrrolidines; Recurrence; Sofosbuvir; Valine; Viral Nonstructural Proteins; Virus Replication | 2021 |
Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection.
Topics: Antiviral Agents; Carbamates; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Treatment Failure; Valine | 2021 |
Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
Topics: Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Morbidity; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Expression profiling of miRNA-196a biomarker in naïve hepatitis C virus-infected and Sofosbuvir plus Daclatasvir-treated patients.
Topics: Adult; Antiviral Agents; Biomarkers; Blood Chemical Analysis; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Host Microbial Interactions; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Pyrrolidines; Real-Time Polymerase Chain Reaction; RNA, Viral; ROC Curve; Sofosbuvir; Valine; Viral Load | 2021 |
Ravidasvir hydrochloride for genotype 1 hepatitis C treatment.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Valine; Viral Nonstructural Proteins | 2021 |
Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cambodia; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Health Services Accessibility; Hepatitis C; Humans; Imidazoles; Male; Mass Screening; Middle Aged; Pilot Projects; Program Evaluation; Public Health; Pyrrolidines; Rural Health Services; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2021 |
Affordable treatment and political commitment are crucial to eliminate hepatitis C globally.
Topics: Benzimidazoles; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Sofosbuvir; Valine | 2021 |
Frailty Status Predicts New Long-term Care Insurance Certification in Hepatitis C Patients Receiving Antiviral Therapy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Eligibility Determination; Female; Frailty; Hepatitis C; Humans; Imidazoles; Insurance, Long-Term Care; Isoquinolines; Japan; Male; Pyrrolidines; Sulfonamides; Valine | 2021 |
Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; India; Kidney Diseases; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2018 |
Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients.
Topics: Acute Disease; Adult; Antiviral Agents; Biomarkers; Carbamates; Creatinine; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; India; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Nephritis, Interstitial; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Time Factors; Valine | 2017 |
Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patients.
Topics: Antiviral Agents; Carbamates; Coinfection; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Pyrrolidines; Treatment Outcome; Valine; Viral Load | 2017 |
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Postoperative Complications; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Pyrrolidines; Sequence Analysis; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2018 |
Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Female; Hepatitis C; Humans; Imidazoles; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Retrospective Studies; Spain; Sustained Virologic Response; Valine | 2017 |
Belgian experience with direct acting antivirals in people who inject drugs.
Topics: Adult; Aged; Antiviral Agents; Belgium; Carbamates; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Simeprevir; Sofosbuvir; Substance Abuse, Intravenous; Valine | 2017 |
Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis.
Topics: Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Disease Progression; Drug Combinations; Drug Compounding; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Japan; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Renal Insufficiency, Chronic; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2017 |
Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil.
Topics: 2-Naphthylamine; Aged; Anilides; Antibiotics, Antineoplastic; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Disease Management; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Mycophenolic Acid; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
Daclatasvir-Sofosbuvir for treatment of hepatitis C virus in patients with inherited bleeding disorders.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genetic Diseases, Inborn; Hemorrhage; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Hepatobiliary and Pancreatic: Rare vascular tumor following treatment for hepatitis C with direct-acting antivirals.
Topics: Aged, 80 and over; Antiviral Agents; Carbamates; Fatal Outcome; Female; Hemangioendothelioma, Epithelioid; Hepatitis C; Humans; Imidazoles; Liver Neoplasms; Palliative Care; Pyrrolidines; Valine | 2017 |
Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience.
Topics: Adult; Aged; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Japan; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prognosis; Protease Inhibitors; Pyrrolidines; Recurrence; Risk Factors; Sulfonamides; Valine | 2017 |
Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2017 |
Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Romania; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine | 2017 |
Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry.
Topics: Animals; Antiviral Agents; Biological Availability; Carbamates; Cell Line, Tumor; Cells, Cultured; Drug Synergism; Drugs, Chinese Herbal; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Humans; Hydrolyzable Tannins; Imidazoles; Mice; Mice, SCID; Paeonia; Plant Extracts; Pyrrolidines; Valine; Virion; Virus Attachment; Virus Replication | 2017 |
Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study.
Topics: Adult; Alleles; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Hepatocyte Nuclear Factor 4; Humans; Imidazoles; Linear Models; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Pyrrolidines; Real-Time Polymerase Chain Reaction; Valine | 2017 |
The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
Topics: Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Carbamates; Cell Line; Cyclosporine; Everolimus; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Pyrrolidines; Sirolimus; Sofosbuvir; Valine; Virus Replication | 2018 |
A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Phenotype; Pyrrolidines; Recurrence; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2018 |
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Imidazoles; Italy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Valine | 2018 |
New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Equatorial Guinea; Female; Fluorenes; Gene Expression; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Microbial Sensitivity Tests; Middle Aged; Mutation; Phylogeny; Proline; Pyrrolidines; Sequence Analysis, DNA; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins | 2018 |
Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrrolidines; Renal Dialysis; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Coinfection; Hepatitis C; HIV Infections; Humans; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Sofosbuvir; Tandem Mass Spectrometry; Valine | 2018 |
Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Case-Control Studies; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Hydroxycholesterols; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sex Factors; Sulfonamides; Treatment Failure; Valine | 2018 |
Comparison between core-shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Imidazoles; Molecular Conformation; Particle Size; Porosity; Pyrrolidines; Simeprevir; Sofosbuvir; Surface Properties; Valine | 2018 |
Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2019 |
Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C-can one size fit all?
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Dogs; Drug Design; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C; Humans; Proline; Silicon; Valine; Viral Nonstructural Proteins | 2018 |
A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection.
Topics: Acute Disease; Adult; Carbamates; China; Drug Therapy, Combination; Early Diagnosis; Early Medical Intervention; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Pyrrolidines; Sofosbuvir; Tattooing; Valine | 2018 |
Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Gene Expression; Hepatitis C; Humans; Imidazoles; Immunity, Innate; Isoquinolines; Killer Cells, Natural; Male; Middle Aged; Pyrrolidines; RNA, Messenger; Sulfonamides; Treatment Outcome; Valine | 2018 |
Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Female; Hepatitis C; Humans; Imidazoles; Incidence; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine | 2018 |
Case report: Identification of recombinant HCV genotype 1b-2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retreatment; RNA, Viral; Sequence Analysis, RNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Valine; Viral Nonstructural Proteins | 2018 |
Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits.
Topics: Animals; Antiviral Agents; Biological Availability; Carbamates; Chromatography, High Pressure Liquid; Drug Combinations; Hepacivirus; Hepatitis C; Imidazoles; Lactones; Limit of Detection; Liquid-Liquid Extraction; Male; Models, Animal; Pyrrolidines; Rabbits; Reproducibility of Results; Sensitivity and Specificity; Sofosbuvir; Spectrophotometry, Ultraviolet; Sulfones; Ultrasonic Waves; Valine | 2018 |
Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
Topics: Animals; Antiviral Agents; Benzazepines; Biomarkers; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Mice; Protease Inhibitors; Pyrrolidines; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins; Viremia | 2018 |
GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.
Topics: Animals; Antiviral Agents; Carbamates; Cell Line, Tumor; Dogs; Drug Combinations; Drug Stability; Drug Synergism; Hepacivirus; Hepatitis C; Humans; Imidazoles; Macrocyclic Compounds; Male; Microsomes, Liver; Mutation; Pyrrolidines; Rats, Sprague-Dawley; Serine Proteases; Serine Proteinase Inhibitors; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2018 |
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine; Young Adult | 2018 |
A Stability-Indicating UPLC Method for the Determination of Potential Impurities and Its Mass by a New QDa Mass Detector in Daclatasvir Drug Used to Treat Hepatitis C Infection.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stability; Hepatitis C; Humans; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Valine | 2019 |
Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.
Topics: Aged; Antiviral Agents; Carbamates; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Isoquinolines; Liver Transplantation; Living Donors; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Sulfonamides; Tacrolimus; Time Factors; Treatment Outcome; Valine; Viral Load | 2018 |
Visualisation and analysis of hepatitis C virus non-structural proteins using super-resolution microscopy.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Microscopy; Pyrrolidines; RNA, Viral; Valine; Viral Nonstructural Proteins; Virus Replication | 2018 |
Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
Topics: 2-Naphthylamine; Anemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Darbepoetin alfa; Female; Hematinics; Hematocrit; Hemoglobin A; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2019 |
The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Using telehealth to improve access to hepatitis C treatment in the direct-acting antiviral therapy era.
Topics: Adult; Aged; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Delivery of Health Care; Female; Fluorenes; Health Services Accessibility; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Telemedicine; Treatment Outcome; Valine | 2020 |
NS5A Promotes Constitutive Degradation of IP3R3 to Counteract Apoptosis Induced by Hepatitis C Virus.
Topics: Animals; Apoptosis; Carbamates; Cell Line; F-Box Proteins; Hepacivirus; Hepatitis C; Humans; Imidazoles; Inositol 1,4,5-Trisphosphate Receptors; Leucine; Protein Multimerization; Proteolysis; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2018 |
Successful Treatment of Fibrosing Cholestatic Hepatitis With Daclatasvir and Asunaprevir After Liver Transplantation: A Case Report.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunocompromised Host; Isoquinolines; Liver Transplantation; Living Donors; Middle Aged; Pyrrolidines; Recurrence; Sulfonamides; Valine | 2018 |
Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA; Sofosbuvir; Sulfonamides; Valine | 2019 |
Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Creatinine; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sodium; Sulfonamides; Uracil; Valine | 2019 |
Sofosbuvir and Daclatsvir in Treatment of Hepatitis C Virus-related Membranoproliferative Glomerulonephritis With Cryoglobulinemia in a Patient With Hepatitis C Genotype 4.
Topics: Antiviral Agents; Carbamates; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C; Humans; Imidazoles; Middle Aged; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2018 |
Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects.
Topics: Adult; Aged; Alanine Transaminase; Algorithms; Benzazepines; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Japan; Male; Middle Aged; Models, Theoretical; Pyrrolidines; Sulfonamides; Valine | 2019 |
Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Topics: Aged; Animals; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cell Line; Chimera; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Guanosine Monophosphate; Hepacivirus; Hepatitis C; Hepatocytes; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Male; Mice; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sequence Deletion; Serine Proteases; Simeprevir; Valine; Viral Nonstructural Proteins | 2019 |
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Evaluation of brain volume alterations in HCV-infected patients after interferon-free therapy: A pilot study.
Topics: Adult; Aged; Anilides; Antiviral Agents; Attention; Brain; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Magnetic Resonance Imaging; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Organ Size; Pilot Projects; Proline; Ritonavir; Sulfonamides; Valine | 2019 |
Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Pakistan; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2019 |
Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus.
Topics: Antiviral Agents; Carbamates; Cells, Cultured; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Oleanolic Acid; Pyrrolidines; Saponins; Valine; Viral Nonstructural Proteins; Virus Replication | 2019 |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Renal Dialysis; Ritonavir; Sulfonamides; Valine; Young Adult | 2019 |
Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation.
Topics: Acute Disease; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Liver Failure; Male; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2019 |
Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis.
Topics: Aged; Antitubercular Agents; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Pyrrolidines; Ribavirin; Sofosbuvir; Tuberculosis; Valine | 2019 |
Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2019 |
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
Topics: Aged; Anemia; Antiviral Agents; Carbamates; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tacrolimus; Valine | 2019 |
Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Industry; Drug Therapy, Combination; Health Services Accessibility; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine | 2014 |
A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity.
Topics: Carbamates; Cell Line; Drug Resistance, Viral; Gene Expression Profiling; Genetic Fitness; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
Topics: Antibodies, Neutralizing; Antiviral Agents; Carbamates; Cell Communication; Cells, Cultured; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Oligopeptides; Proline; Pyrrolidines; Valine; Viral Load; Virus Internalization | 2014 |
In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.
Topics: Anilides; Antiviral Agents; Carbamates; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Proline; Valine | 2015 |
Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
Topics: Antiviral Agents; Carbamates; Cell Line; Hepacivirus; Hepatitis C; Humans; Imidazoles; Minor Histocompatibility Antigens; Phosphatidylinositols; Phosphotransferases (Alcohol Group Acceptor); Protein Binding; Protein Transport; Pyrrolidines; RNA-Dependent RNA Polymerase; Valine; Viral Nonstructural Proteins; Virus Replication | 2015 |
Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Lactams, Macrocyclic; Macrocyclic Compounds; Polyethylene Glycols; Proline; Ribavirin; RNA-Dependent RNA Polymerase; Sulfonamides; Uracil; Valine | 2015 |
A novel method for the measurement of hepatitis C virus infectious titres using the IncuCyte ZOOM and its application to antiviral screening.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Fluorescent Antibody Technique; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Microbial Sensitivity Tests; Pyrrolidines; RNA, Viral; Sofosbuvir; Valine; Viral Load; Virus Replication | 2015 |
HIV-hepatitis C co-infection.
Topics: Antiviral Agents; Carbamates; Coinfection; Hepatitis C; HIV Infections; Humans; Imidazoles; Pyrrolidines; Randomized Controlled Trials as Topic; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine | 2015 |
[Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA].
Topics: Anti-HIV Agents; Carbamates; Drug Combinations; Gastroenterology; Germany; Hepatitis C; Imidazoles; Internal Medicine; Pyrrolidines; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine | 2015 |
Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Imidazoles; Mutation, Missense; Phylogeny; Polymerase Chain Reaction; Polymorphism, Genetic; Prevalence; Protease Inhibitors; Pyrrolidines; Sequence Analysis; Sweden; Valine; Viral Nonstructural Proteins | 2015 |
A 4-drug combination (Viekira Pak) for hepatitis C.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
Topics: Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Valine; Viral Load; Virus Activation | 2015 |
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
Topics: Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Gene Expression Regulation, Viral; Genotype; Global Health; Hepacivirus; Hepatitis C; Humans; Imidazoles; Phylogeny; Polymorphism, Genetic; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2016 |
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Standard of Care; Treatment Outcome; Valine | 2016 |
Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; China; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Male; Middle Aged; Polymorphism, Genetic; Pyrrolidines; Simeprevir; Valine | 2015 |
Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Genotype; Graft Survival; Hepacivirus; Hepatitis C; HIV Infections; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Uracil; Valine | 2016 |
Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
Topics: Allosteric Regulation; Animals; Antiviral Agents; Biphenyl Compounds; Carbamates; Cell Line; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imidazoles; Mice; Models, Molecular; Protein Conformation; Protein Multimerization; Protein Structure, Quaternary; Pyrrolidines; Reproducibility of Results; Valine; Viral Nonstructural Proteins; Virus Replication | 2015 |
Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.
Topics: Animals; Antiviral Agents; Carbamates; Chimera; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imidazoles; Isoquinolines; Mice; Mutation; Pyrrolidines; Sulfonamides; Valine | 2016 |
Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Costs; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Economic; Phenotype; Proline; Recurrence; Ribavirin; Risk Factors; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; United States; Uracil; Valine; Viral Load; Virus Activation | 2016 |
Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Atazanavir Sulfate; Carbamates; Coinfection; Cyclopropanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Function Tests; Liver Neoplasms; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2016 |
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Valine; Viral Load; Young Adult | 2016 |
Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients.
Topics: 2-Naphthylamine; Anilides; Carbamates; Coinfection; Cyclopropanes; Darunavir; Hepatitis C; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Department of Veterans Affairs; Uracil; Uridine Monophosphate; Valine | 2016 |
Successful treatment of hepatitis C virus infection combining daclatasvir and simeprevir in a heart transplant recipient with decompensated cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Heart Transplantation; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Simeprevir; Valine | 2016 |
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Female; Fluorenes; Health Services Accessibility; Hepacivirus; Hepatitis C; HIV Protease Inhibitors; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Markov Chains; Medicaid; Middle Aged; Proline; Ritonavir; Severity of Illness Index; Sofosbuvir; Sulfonamides; United States; Uracil; Uridine Monophosphate; Valine | 2016 |
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Breast Hypertrophy Induced by Ombitasvir/Paritaprevir/Ritonavir and Ribavirina.
Topics: Anilides; Antiviral Agents; Breast Diseases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hypertrophy; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine | 2016 |
Falling up stairs.
Topics: 2-Naphthylamine; Accidental Falls; Anilides; Antiviral Agents; Bronchodilator Agents; Carbamates; Cushing Syndrome; Cyclopropanes; Drug Therapy, Combination; Fluticasone; Hepatitis C; Humans; Hydrocortisone; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Salmeterol Xinafoate; Sulfonamides; Uracil; Valine | 2016 |
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Female; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
Inhibitory effect of presenilin inhibitor LY411575 on maturation of hepatitis C virus core protein, production of the viral particle and expression of host proteins involved in pathogenicity.
Topics: Alanine; Antiviral Agents; Azepines; Carbamates; Cell Line; Cell Survival; Cells, Cultured; Drug Synergism; Gene Expression Regulation; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Imidazoles; Oxidative Stress; Presenilins; Proteolysis; Pyrrolidines; Reactive Oxygen Species; Valine; Viral Core Proteins; Virus Replication | 2016 |
First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Kazakhstan; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Medication Adherence; Proline; Recurrence; Retreatment; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Waiting Lists | 2016 |
[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation].
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppression Therapy; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Postoperative Complications; Proline; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Sulfonamides; Treatment Outcome; Valine | 2016 |
A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry.
Topics: Antiviral Agents; Carbamates; Computational Biology; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Phosphoproteins; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2016 |
Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
Topics: Alleles; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Polymorphism, Genetic; Pyrrolidines; Ribavirin; Sequence Analysis, DNA; Sofosbuvir; Treatment Failure; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins | 2017 |
Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Carbamates; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Phylogeny; Pyrrolidines; Serotyping; Sulfonamides; Time Factors; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2017 |
Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.
Topics: Animals; Anti-Retroviral Agents; Carbamates; Drug Resistance, Viral; Evolution, Molecular; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Mice; Mutation; Phylogeny; Pyrrolidines; Selection, Genetic; Sulfonamides; Valine | 2017 |
Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Ribavirin; Ritonavir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2017 |
Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvir.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Hepatitis C; Imidazoles; Limit of Detection; Pharmaceutical Solutions; Pyrrolidines; Reproducibility of Results; Tablets; Valine | 2017 |
Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Practice Patterns, Physicians'; Proline; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine; Veterans | 2017 |
Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure.
Topics: Acute Disease; Administration, Oral; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Failure, Acute; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Valine | 2017 |
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
Topics: Aged; Antiviral Agents; B-Lymphocyte Subsets; Biomarkers; Carbamates; Case-Control Studies; Cryoglobulinemia; Cytokines; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis Viruses; Humans; Imidazoles; Immune Tolerance; Immunity, Cellular; Male; Middle Aged; Phenotype; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; T-Lymphocyte Subsets; Time Factors; Treatment Outcome; Valine; Vasculitis; Viral Load | 2017 |
[Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Biliary Tract Diseases; Carbamates; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Kidney Calculi; Lamivudine; Lithiasis; Male; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Valine | 2017 |
Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis.
Topics: Antiviral Agents; B-Lymphocytes; Carbamates; CD4-Positive T-Lymphocytes; Cryoglobulinemia; Cryoglobulins; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Immunoglobulin M; Interleukins; Lymphocyte Count; Male; Middle Aged; Prospective Studies; Pyrrolidines; Receptors, Complement 3d; Receptors, CXCR5; Sofosbuvir; Sustained Virologic Response; T-Lymphocytes, Regulatory; Th17 Cells; Valine; Vasculitis | 2017 |
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Exanthema; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; RNA, Viral; Sulfonamides; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2017 |
[BMS-790 052 - an oral antiviral hepatitis C antiviral in the pipeline].
Topics: Antiviral Agents; Carbamates; Germany; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; RNA, Viral; Valine | 2011 |
The end of the beginning for hepatitis C treatment.
Topics: Antiviral Agents; Carbamates; Enzyme Inhibitors; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Male; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine; Viral Nonstructural Proteins | 2012 |
A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine.
Topics: Carbamates; Chromatography, Liquid; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liquid-Liquid Extraction; Pyrrolidines; Sensitivity and Specificity; Tandem Mass Spectrometry; Valine; Viral Nonstructural Proteins | 2012 |
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Molecular Sequence Data; Prevalence; Protease Inhibitors; Pyrrolidines; Sequence Analysis, DNA; Valine; Viral Nonstructural Proteins; Young Adult | 2012 |
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.
Topics: Alkaline Phosphatase; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cholestasis; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Liver Failure; Liver Transplantation; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Recurrence; Reoperation; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Valine; Viral Load | 2012 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Famciclovir; Guanine; Hepatitis B; Hepatitis C; Herpes Simplex; Herpes Zoster; Humans; Influenza, Human; Valacyclovir; Valine; Virus Diseases | 2005 |
Genetic polymorphism in the manganese superoxide dismutase gene is associated with an increased risk for hepatocellular carcinoma in HCV-infected Moroccan patients.
Topics: Aged; Alanine; Carcinoma, Hepatocellular; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatitis C; Humans; Male; Middle Aged; Morocco; Odds Ratio; Polymorphism, Genetic; Risk Factors; Superoxide Dismutase; Valine | 2008 |
Critical role of Val/Gly86 HLA-DRB dimorphism in the neonatal resistance or susceptibility to maternal hepatitis C virus infection.
Topics: Female; Gene Frequency; Glycine; Haplotypes; Hepatitis C; HLA-DR Antigens; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Polymerase Chain Reaction; Polymorphism, Genetic; Pregnancy; Pregnancy Complications, Infectious; Valine | 1997 |